Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials
Authors
Keywords
-
Journal
Journal of Diabetes Research
Volume 2015, Issue -, Pages 1-14
Publisher
Hindawi Limited
Online
2015-05-15
DOI
10.1155/2015/606031
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- DPP4 in Cardiometabolic Disease: Recent Insights From the Laboratory and Clinical Trials of DPP4 Inhibition
- (2015) J. Zhong et al. CIRCULATION RESEARCH
- Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors
- (2015) Jixin Zhong et al. Clinical Lipidology
- Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study
- (2015) Reimar Wernich Thomsen et al. DIABETES CARE
- Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials
- (2014) Nayyar Iqbal et al. Cardiovascular Diabetology
- DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study
- (2014) Kazufumi Nakamura et al. Cardiovascular Diabetology
- Dipeptidyl Peptidase-4 Inhibitors and Cardiovascular Outcomes: Meta-Analysis of Randomized Clinical Trials with 55,141 Participants
- (2014) Shiying Wu et al. Cardiovascular Therapeutics
- Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
- (2014) Benjamin M. Scirica et al. CIRCULATION
- Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
- (2014) Erin E. Mulvihill et al. ENDOCRINE REVIEWS
- Exenatide protects against hypoxia/reoxygenation-induced apoptosis by improving mitochondrial function in H9c2 cells
- (2014) Guanglei Chang et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- Hope and fear for new classes of type 2 diabetes drugs: is there preclinical evidence that incretin-based therapies alter pancreatic morphology?
- (2014) Benjamin J Lamont et al. JOURNAL OF ENDOCRINOLOGY
- Mouse Dipeptidyl Peptidase 4 Is Not a Functional Receptor for Middle East Respiratory Syndrome Coronavirus Infection
- (2014) A. S. Cockrell et al. JOURNAL OF VIROLOGY
- Saxagliptin, Alogliptin, and Cardiovascular Outcomes
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomized clinical trials
- (2014) M. Monami et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Do Dipeptidyl Peptidase-4 Inhibitors Increase the Risk of Heart Failure? ∗
- (2014) Deepak L. Bhatt et al. JACC-Heart Failure
- Sitagliptin Use in Patients With Diabetes and Heart Failure
- (2014) Daniala L. Weir et al. JACC-Heart Failure
- Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials
- (2013) M. Monami et al. DIABETES OBESITY & METABOLISM
- Dipeptidylpeptidase Inhibition Is Associated with Improvement in Blood Pressure and Diastolic Function in Insulin-Resistant Male Zucker Obese Rats
- (2013) Annayya R. Aroor et al. ENDOCRINOLOGY
- CD26/DPP4 Levels in Peripheral Blood and T Cells in Patients With Type 2 Diabetes Mellitus
- (2013) Sang Ah Lee et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Adenosine Deaminase Acts as a Natural Antagonist for Dipeptidyl Peptidase 4-Mediated Entry of the Middle East Respiratory Syndrome Coronavirus
- (2013) V. S. Raj et al. JOURNAL OF VIROLOGY
- Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26
- (2013) Guangwen Lu et al. NATURE
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dipeptidyl Peptidase‐4 Inhibitors Attenuate Endothelial Function as Evaluated by Flow‐Mediated Vasodilatation in Type 2 Diabetic Patients
- (2013) Makoto Ayaori et al. Journal of the American Heart Association
- Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus
- (2013) Sonal Singh et al. JAMA Internal Medicine
- Meta-Analysis of Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Risk in Type 2 Diabetes Mellitus
- (2012) Harshal R. Patil et al. AMERICAN JOURNAL OF CARDIOLOGY
- An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: Potential implications in cardiovascular disease
- (2012) Jixin Zhong et al. ATHEROSCLEROSIS
- Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells
- (2012) Chun-Yao Huang et al. BRITISH JOURNAL OF PHARMACOLOGY
- Dipeptidyl Peptidase-4 Modulates Left Ventricular Dysfunction in Chronic Heart Failure via Angiogenesis-Dependent and -Independent Actions
- (2012) Toshimasa Shigeta et al. CIRCULATION
- A Potential Role for Dendritic Cell/Macrophage-Expressing DPP4 in Obesity-Induced Visceral Inflammation
- (2012) Jixin Zhong et al. DIABETES
- Cardiovascular effects of the DPP-4 inhibitors
- (2012) Tessey Jose et al. Diabetes & Vascular Disease Research
- Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials
- (2012) M. Monami et al. DIABETES OBESITY & METABOLISM
- Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety
- (2012) D. Nathanson et al. DIABETOLOGIA
- Cardiovascular Biology of the Incretin System
- (2012) John R. Ussher et al. ENDOCRINE REVIEWS
- GLP1 and cancer: friend or foe?
- (2012) Roman Vangoitsenhoven et al. ENDOCRINE-RELATED CANCER
- Dipeptidyl Peptidase-4 Inhibition With Saxagliptin Enhanced Nitric Oxide Release and Reduced Blood Pressure and sICAM-1 Levels in Hypertensive Rats
- (2012) R. Preston Mason et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Human Th17 Cells Express High Levels of Enzymatically Active Dipeptidylpeptidase IV (CD26)
- (2012) B. Bengsch et al. JOURNAL OF IMMUNOLOGY
- A Dipeptidyl Peptidase-4 Inhibitor, Des-Fluoro-Sitagliptin, Improves Endothelial Function and Reduces Atherosclerotic Lesion Formation in Apolipoprotein E–Deficient Mice
- (2012) Junichi Matsubara et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of Heart Failure on Dipeptidyl Peptidase IV Activity in Plasma of Dogs
- (2012) N. Gomez et al. JOURNAL OF VETERINARY INTERNAL MEDICINE
- Renal and Cardiac Effects of DPP-4 Inhibitors from Preclinical Development to Clinical Research
- (2012) Berthold Hocher et al. KIDNEY & BLOOD PRESSURE RESEARCH
- Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis
- (2012) Hal E Broxmeyer et al. NATURE MEDICINE
- Adaptive immunity in obesity and insulin resistance
- (2012) Henrike Sell et al. Nature Reviews Endocrinology
- Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy
- (2011) Anthony H. Barnett ADVANCES IN THERAPY
- Linagliptin approved for type 2 diabetes
- (2011) K. Traynor AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes
- (2011) Susana Ravassa et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury
- (2011) Hiromasa Goto et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis
- (2011) Zubair Shah et al. CIRCULATION
- Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes
- (2011) P. C. M. van Poppel et al. DIABETES CARE
- The Possible Protective Role of Glucagon-Like Peptide 1 on Endothelium During the Meal and Evidence for an "Endothelial Resistance" to Glucagon-Like Peptide 1 in Diabetes
- (2011) A. Ceriello et al. DIABETES CARE
- Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice
- (2011) M. Nagashima et al. DIABETOLOGIA
- Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies
- (2011) Michael Elashoff et al. GASTROENTEROLOGY
- Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease
- (2011) Philip A Read et al. HEART
- Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism
- (2011) Masayuki Miyazaki Molecular Medicine Reports
- Upregulation of CD26 expression in epithelial cells and stromal cells during wound-induced skin tumour formation
- (2011) E N Arwert et al. ONCOGENE
- Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways
- (2011) Zubair Shah et al. VASCULAR PHARMACOLOGY
- Altered dipeptidyl peptidase-4 activity during the progression of hyperinsulinemic obesity and islet atrophy in spontaneously late-stage type 2 diabetic rats
- (2010) Yasushi Kirino et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Pre-treatment with a DPP-4 Inhibitor is Infarct Sparing in Hearts from Obese, Pre-diabetic Rats
- (2010) Barbara Huisamen et al. CARDIOVASCULAR DRUGS AND THERAPY
- Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake via p38α MAP Kinase–Mediated, Nitric Oxide–Dependent Mechanisms in Conscious Dogs With Dilated Cardiomyopathy
- (2010) Siva Bhashyam et al. Circulation-Heart Failure
- Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
- (2010) M. Arakawa et al. DIABETES
- Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice
- (2010) M. Sauve et al. DIABETES
- Weight Loss, Glycemic Control, and Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort Database
- (2010) E. S. Horton et al. DIABETES CARE
- The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes: Possible role of stromal-derived factor-1
- (2010) G. P. Fadini et al. DIABETES CARE
- DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
- (2010) J. B. Buse et al. DIABETES CARE
- Inhibition of multifunctional dipeptidyl peptidase-IV: Is there a risk of oncological and immunological adverse effects?
- (2010) Tomas Stulc et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- RETRACTED ARTICLE: A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells
- (2010) Y. Hattori et al. DIABETOLOGIA
- Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor
- (2010) Ö. Erdogdu et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
- (2009) Carolyn F. Deacon et al. ADVANCES IN THERAPY
- FDA approves saxagliptin for type 2 diabetes
- (2009) K. Traynor AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model
- (2009) Kunio Hirata et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
- (2009) M. H. Noyan-Ashraf et al. DIABETES
- The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice
- (2009) J. Hsieh et al. DIABETOLOGIA
- Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials
- (2009) M. Monami et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- DPP4 inhibitors for diabetes—What next?
- (2008) Anne-Marie Lambeir et al. BIOCHEMICAL PHARMACOLOGY
- New Drugs for the Treatment of Diabetes
- (2008) Silvio E. Inzucchi et al. CIRCULATION
- Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways
- (2008) Kiwon Ban et al. CIRCULATION
- Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects
- (2007) Aine M. McKillop et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Role of CD26/dipeptidyl peptidase IV in human T cell activation and function
- (2007) Kei Ohnuma Frontiers in Bioscience-Landmark
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now